(RTTNews.com) - Biogen Idec ( BIIB ) Thursday announced results from several new analyses of Tysabri (natalizumab) data that demonstrate its effectiveness in reducing multiple sclerosis or MS disease activity.
According to the drugmaker, this effect was particularly significant in people with relapsing MS who initiated treatment when they had lower Expanded Disability Status Scale or EDSS scores as well as in those who have been treated for more than two years.
Alfred Sandrock, group senior vice president, Development Sciences and Chief Medical Officer, Biogen Idec, said, "These analyses build upon a growing body of evidence that demonstrates greater clinical benefits for people with MS when TYSABRI is initiated earlier in the course of the disease, as well as when TYSABRI is used for a longer duration in appropriate patients."
These data will be presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis or ECTRIMS in Copenhagen, Denmark from October 2-5.
For comments and feedback: contact firstname.lastname@example.org
USE OUR SHARE LINKS at the top of this page - to provide this article to others